<p>K.J. Harrison &amp; Partners Inc 在第二季度根据其最近向证券交易委员会提交的 13F 表格购买了 Regeneron Pharmaceuticals, Inc.（NASDAQ:REGN - 免费报告）的新股份。这家机构投资者购买了 2,001 股这家生物制药公司的股票，价值约为 1,051,000 美元。</p>
<ul>
<li>大熊星座：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>其他几家机构投资者和对冲基金也增加或减少了在 REGN 的持股。PGGM Investments 在第二季度将其在 Regeneron Pharmaceuticals 的股份增加了 159.7%。PGGM Investments 目前拥有 84,397 股这家生物制药公司的股票，价值 4,430,800 美元，此前在上个季度购买了 51,900 股。Founders Capital Management LLC 在第二季度将其在 Regeneron Pharmaceuticals 的股份增加了 7.0%。Founders Capital Management LLC 目前拥有 8,274 股这家生物制药公司的股票，价值 4,344,000 美元，此前在上个季度购买了 538 股。Sepio Capital LP 在第一季度将其在 Regeneron Pharmaceuticals 的股份增加了 33.1%。Sepio Capital LP 目前拥有 3,389 股这家生物制药公司的股票，价值 2,150,000 美元，此前在上个季度购买了 842 股。China Universal Asset Management Co. Ltd.在第一季度将其在 Regeneron Pharmaceuticals 的股份增加了 3.9%。China Universal Asset Management Co. Ltd.目前拥有 25,629 股这家生物制药公司的股票，价值 16,255,000 美元，此前在上个季度购买了 955 股。最后，Generate Investment Management Ltd 在第二季度获得了 Regeneron Pharmaceuticals 的新头寸，价值 6,300,000 美元。83.31% 的股票由机构投资者和对冲基金持有。</p>
<h2>Regeneron Pharmaceuticals 价格表现</h2>
<p>NASDAQ:REGN 周一开盘价为 651.80 美元。该公司的 50 日移动平均线为 581.80 美元，200 日移动平均线为 565.38 美元。该公司的市值为 690.8 亿美元，市盈率为 15.61，PEG 比率为 2.03，贝塔值为 0.31。Regeneron Pharmaceuticals, Inc.的 52 周低点为 476.49 美元，52 周高点为 883.15 美元。该公司的债务与股本比率为 0.09，速动比率为 3.72，流动比率为 4.06。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p>Regeneron Pharmaceuticals（NASDAQ:REGN - 获取免费报告）最近于 10 月 28 日星期二发布了季度财报。这家生物制药公司报告季度每股收益为 11.83 美元，超出分析师一致预期的 9.73 美元，超出幅度为 2.10 美元。该公司在本季度的收入为 37.5 亿美元，而一致预期为 35.7 亿美元。Regeneron Pharmaceuticals 的净利润率为 32.13%，股本回报率为 13.76%。该公司本季度的收入较去年同期增长了 0.9%。去年同期，该公司每股收益为 12.46 美元。整体来看，股票研究分析师预计 Regeneron Pharmaceuticals, Inc.在本财年的每股收益将达到 35.92 美元。</p>
<h2>Regeneron Pharmaceuticals 股息公告</h2>
<p>该公司最近宣布了一项季度股息，将于 12 月 5 日星期五支付。11 月 20 日星期四的登记投资者将获得每股 0.88 美元的股息。这代表着每年 3.52 美元的股息和 0.5% 的收益率。该股息的除息日期为 11 月 20 日星期四。Regeneron Pharmaceuticals 的股息支付比率（DPR）目前为 8.43%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 只具有坚固资产负债表的股票，适合长期稳定投资</li>
</ul>
<p>REGN 已成为多份研究分析师报告的主题。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Regeneron Pharmaceuticals 股票的 “持有（c-）” 评级。Cantor Fitzgerald 在 10 月 29 日星期三的研究报告中将 Regeneron Pharmaceuticals 的目标价从 678.00 美元上调至 740.00 美元，并给予该公司 “增持” 评级。Redburn Atlantic 在 8 月 14 日星期四的研究报告中将 Regeneron Pharmaceuticals 的股票评级上调至 “强烈买入”。Guggenheim 在 10 月 29 日星期三的报告中将 Regeneron Pharmaceuticals 的目标价从 815.00 美元上调至 865.00 美元，并给予该公司 “买入” 评级。最后，加拿大皇家银行在 10 月 29 日星期三的报告中将 Regeneron Pharmaceuticals 的目标价从 704.00 美元上调至 708.00 美元，并给予该公司 “行业表现” 评级。三位股票研究分析师对该股给予了 “强烈买入” 评级，十六位给予了 “买入” 评级，七位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Regeneron Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 802.36 美元。</p>
<p><strong>查看我们关于 REGN 的最新研究报告</strong></p>
<h2>Regeneron Pharmaceuticals 的内部交易</h2>
<p>在相关消息中，董事 Christine A. Poon 在 10 月 29 日星期三的交易中出售了 6,500 股 Regeneron Pharmaceuticals 的股票。这些股票以 654.27 美元的平均价格出售，总交易额为 4,252,755.00 美元。交易完成后，该董事直接持有该公司 2,352 股股票，价值 1,538,843.04 美元。这笔交易代表着其持股比例减少了 73.43%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。7.02% 的股票由公司内部人士持有。</p>
<h2>关于 Regeneron Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>再生元制药公司发现、发明、开发、制造并商业化用于治疗全球各种疾病的药物。公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病；新生血管性青光眼；以及早产儿视网膜病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过再生元制药</li>
<li>最大的股票亏损者 - 今日最大百分比下跌者</li>
<li>适合任何市场的三只安全稳健股票</li>
<li>什么是支撑位？</li>
<li>Lemonade 股票在财报后是否会迎来大幅反弹？</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>卡特彼勒股票到年底可能超过 650 美元</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在再生元制药吗？</h2>
<p>在你考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而再生元制药并不在名单上。</p>
<p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>K.J. Harrison & Partners Inc 在第二季度收购了再生元制药的新股份，购买了 2,001 股，价值约为 105 万美元。其他机构投资者也增加了他们的持股。再生元报告了强劲的季度收益，超出预期，每股收益为 11.83 美元，收入为 37.5 亿美元。公司宣布每股季度分红为 0.88 美元，收益率为 0.5%。分析师对该股票的评级各异，目标价格范围从 678 美元到 865 美元</p>

<p>K.J. Harrison &amp; Partners Inc bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor bought 2,001 shares of the biopharmaceutical company's stock, valued at approximately $1,051,000.</p>
<div class="lb-trans"><p>K.J. Harrison &amp; Partners Inc 在第二季度根据其最近向证券交易委员会提交的 13F 表格购买了 Regeneron Pharmaceuticals, Inc.（NASDAQ:REGN - 免费报告）的新股份。这家机构投资者购买了 2,001 股这家生物制药公司的股票，价值约为 1,051,000 美元。</p>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大熊星座：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. PGGM Investments increased its stake in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock worth $44,308,000 after purchasing an additional 51,900 shares during the last quarter. Founders Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after buying an additional 538 shares during the last quarter. Sepio Capital LP grew its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares during the last quarter. Finally, Generate Investment Management Ltd acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $6,300,000. 83.31% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也增加或减少了在 REGN 的持股。PGGM Investments 在第二季度将其在 Regeneron Pharmaceuticals 的股份增加了 159.7%。PGGM Investments 目前拥有 84,397 股这家生物制药公司的股票，价值 4,430,800 美元，此前在上个季度购买了 51,900 股。Founders Capital Management LLC 在第二季度将其在 Regeneron Pharmaceuticals 的股份增加了 7.0%。Founders Capital Management LLC 目前拥有 8,274 股这家生物制药公司的股票，价值 4,344,000 美元，此前在上个季度购买了 538 股。Sepio Capital LP 在第一季度将其在 Regeneron Pharmaceuticals 的股份增加了 33.1%。Sepio Capital LP 目前拥有 3,389 股这家生物制药公司的股票，价值 2,150,000 美元，此前在上个季度购买了 842 股。China Universal Asset Management Co. Ltd.在第一季度将其在 Regeneron Pharmaceuticals 的股份增加了 3.9%。China Universal Asset Management Co. Ltd.目前拥有 25,629 股这家生物制药公司的股票，价值 16,255,000 美元，此前在上个季度购买了 955 股。最后，Generate Investment Management Ltd 在第二季度获得了 Regeneron Pharmaceuticals 的新头寸，价值 6,300,000 美元。83.31% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Regeneron Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Regeneron Pharmaceuticals 价格表现</h2>
</div><p>NASDAQ:REGN opened at $651.80 on Monday. The company has a 50-day moving average of $581.80 and a 200-day moving average of $565.38. The company has a market capitalization of $69.08 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $883.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.</p>
<div class="lb-trans"><p>NASDAQ:REGN 周一开盘价为 651.80 美元。该公司的 50 日移动平均线为 581.80 美元，200 日移动平均线为 565.38 美元。该公司的市值为 690.8 亿美元，市盈率为 15.61，PEG 比率为 2.03，贝塔值为 0.31。Regeneron Pharmaceuticals, Inc.的 52 周低点为 476.49 美元，52 周高点为 883.15 美元。该公司的债务与股本比率为 0.09，速动比率为 3.72，流动比率为 4.06。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm's revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm earned $12.46 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Regeneron Pharmaceuticals（NASDAQ:REGN - 获取免费报告）最近于 10 月 28 日星期二发布了季度财报。这家生物制药公司报告季度每股收益为 11.83 美元，超出分析师一致预期的 9.73 美元，超出幅度为 2.10 美元。该公司在本季度的收入为 37.5 亿美元，而一致预期为 35.7 亿美元。Regeneron Pharmaceuticals 的净利润率为 32.13%，股本回报率为 13.76%。该公司本季度的收入较去年同期增长了 0.9%。去年同期，该公司每股收益为 12.46 美元。整体来看，股票研究分析师预计 Regeneron Pharmaceuticals, Inc.在本财年的每股收益将达到 35.92 美元。</p>
</div><h2>Regeneron Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>Regeneron Pharmaceuticals 股息公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.43%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，将于 12 月 5 日星期五支付。11 月 20 日星期四的登记投资者将获得每股 0.88 美元的股息。这代表着每年 3.52 美元的股息和 0.5% 的收益率。该股息的除息日期为 11 月 20 日星期四。Regeneron Pharmaceuticals 的股息支付比率（DPR）目前为 8.43%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 Stocks With Ironclad Balance Sheets for Long-Term Stability</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有坚固资产负债表的股票，适合长期稳定投资</li>
</ul>
</div><p>REGN has been the topic of a number of research analyst reports. Weiss Ratings reiterated a &#34;hold (c-)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 29th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Thursday, August 14th. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a &#34;sector perform&#34; rating in a report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $802.36.</p>
<div class="lb-trans"><p>REGN 已成为多份研究分析师报告的主题。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Regeneron Pharmaceuticals 股票的 “持有（c-）” 评级。Cantor Fitzgerald 在 10 月 29 日星期三的研究报告中将 Regeneron Pharmaceuticals 的目标价从 678.00 美元上调至 740.00 美元，并给予该公司 “增持” 评级。Redburn Atlantic 在 8 月 14 日星期四的研究报告中将 Regeneron Pharmaceuticals 的股票评级上调至 “强烈买入”。Guggenheim 在 10 月 29 日星期三的报告中将 Regeneron Pharmaceuticals 的目标价从 815.00 美元上调至 865.00 美元，并给予该公司 “买入” 评级。最后，加拿大皇家银行在 10 月 29 日星期三的报告中将 Regeneron Pharmaceuticals 的目标价从 704.00 美元上调至 708.00 美元，并给予该公司 “行业表现” 评级。三位股票研究分析师对该股给予了 “强烈买入” 评级，十六位给予了 “买入” 评级，七位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Regeneron Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 802.36 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on REGN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 REGN 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>Regeneron Pharmaceuticals 的内部交易</h2>
</div><p>In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company's stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.02% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Christine A. Poon 在 10 月 29 日星期三的交易中出售了 6,500 股 Regeneron Pharmaceuticals 的股票。这些股票以 654.27 美元的平均价格出售，总交易额为 4,252,755.00 美元。交易完成后，该董事直接持有该公司 2,352 股股票，价值 1,538,843.04 美元。这笔交易代表着其持股比例减少了 73.43%。该出售在向 SEC 提交的文件中披露，文件可在此链接查看。7.02% 的股票由公司内部人士持有。</p>
</div><h2>About Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Regeneron Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元制药公司发现、发明、开发、制造并商业化用于治疗全球各种疾病的药物。公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病；新生血管性青光眼；以及早产儿视网膜病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>3 Safe and Steady Stocks for Any Market</li>
<li>What is a support level?</li>
<li>Is Lemonade Stock Set for a Big Squeeze After Earnings?</li>
<li>What is MarketRank™? How to Use it</li>
<li>Caterpillar Stock Could Top $650 by Year’s End</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过再生元制药</li>
<li>最大的股票亏损者 - 今日最大百分比下跌者</li>
<li>适合任何市场的三只安全稳健股票</li>
<li>什么是支撑位？</li>
<li>Lemonade 股票在财报后是否会迎来大幅反弹？</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>卡特彼勒股票到年底可能超过 650 美元</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

K.J. Harrison & Partners Inc 购入了再生元制药公司（Regeneron Pharmaceuticals, Inc.）的新股票 $REGN